FDA under fire over approval of Alzheimer’s drug Aduhelm
House of Representatives’ report details ‘corporate greed’ and ‘atypical review process’ preceding agency’s approval of Biogen’s drug
US drug regulators failed to follow their own guidance and practices when they approved the controversial Alzheimer’s drug Aduhelm, a congressional report said on Thursday.
The US food and drug administration’s (FDA) process of approval, it said, had been “rife with irregularities”, and the FDA’s interactions with maker Biogen had been “atypical”.
